Article info
Clinical and epidemiological research
Extended report
A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease
- Correspondence to Dr Raphaela Goldbach-Mansky, Translational Autoinflammatory Section, NIH/NIAMS, Building 10 Room 6D47-B, 10 Center Dr., Bethesda, MD 20892, USA; goldbacr{at}mail.nih.gov
Citation
A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease
Publication history
- Received November 11, 2013
- Revised March 21, 2014
- Accepted April 13, 2014
- First published June 6, 2014.
Online issue publication
August 10, 2015
Article Versions
- Previous version (6 June 2014).
- Previous version (23 July 2014).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions